Credit: Officials with Gaithersburg-based Novavax Inc. said Wednesday they will lay off 30 percent of their workforce as they scramble to rework the company’s pipeline following a failed phase 3 clinical trial of its lead respiratory syncytial virus vaccine candidate for older adults.
Novavax to cut 30 percent of its workforce
